Skip to Content

Join the 'Aspergillosis' group to help and get support from people like you.

Aspergillosis News

FDA Approves Cresemba (isavuconazonium sulfate) For Fungal Infections

Posted 6 Mar 2015 by Drugs.com

March 6, 2015 – The U.S. Food and Drug Administration today approved Cresemba (isavuconazonium sulfate), a new antifungal drug product used to treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections. Aspergillosis is a fungal infection caused by Aspergillus species, and mucormycosis is caused by the Mucorales fungi. These infections occur most often in people with weakened immune systems. Cresemba belongs to a class of drugs called azole antifungal agents, which target the cell wall of a fungus. Cresemba is available in oral and intravenous formulations. “Today’s approval provides a new treatment option for patients with serious fungal infections and underscores the importance of having available safe and effective antifungal drugs,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Eval ... Read more

Related support groups: Fungal Infections, Aspergillosis, Aspergillosis - Invasive

FDA Approves Merck’s Noxafil Delayed-Release Tablets

Posted 26 Nov 2013 by Drugs.com

WHITEHOUSE STATION, N.J., Nov. 26, 2013--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Noxafil (posaconazole) 100 mg delayed-release tablets. Noxafil delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Merck also markets Noxafil (40 mg/mL) oral suspension, which is dosed three times daily. Noxafil delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as ... Read more

Related support groups: Candida Infections, Candida, Aspergillosis, Noxafil, Posaconazole

Ask a Question

Further Information

Related Condition Support Groups

Aspergillosis - Invasive, Aspergillosis - Aspergilloma, Aspergillosis - Meningitis with 5-FC, Aspergillosis - Meningitis, Systemic Fungal Infection